Announcements Trials
Browse Landscape

Status

Completed 1431Unknown 512Recruiting 412Terminated 328Active not recruiting 250Not yet recruiting 122Withdrawn 119Enrolling by invitation 9Suspended 8No longer available 1Approved for marketing 1

Sponsor Class

INDUSTRY 1

Study Type

Expanded_access 1

Sponsor

Cancer Type

Thoracic 1Other solid neoplasm 1

Conditions

Mesothelioma 1

Interventions

Afatinib 33-Iodobenzylguanidine 3niraparib 2lenvatinib 2ibrutinib 2gallium 68 PSMA-11 2abemaciclib 2Trastuzumab 2Sunitinib 2Ramucirumab 2Oxaliplatin 2Magnetic Resonance Spectroscopy 2Gefitinib 2Fluorouracil 2Capecitabine 2Amifampridine 2Abiraterone Acetate 2zenocutuzumab 1vorasidenib 1tucatinib 1trilaciclib 1trifluridine tipiracil drug combination 1tovorafenib 1talquetamab 1tafasitamab 1selpercatinib 1sacituzumab govitecan 1ripretinib 1pralsetinib 1ponatinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Approved for marketing × Cisplatin × Clear all
NCT00040625 2007-03-15

ALIMTA (Pemetrexed) Alone or in Combination With Cisplatin for Patients With Malignant Mesothelioma.

Eli Lilly and Company

Approved for marketing
Other solid neoplasmThoracic

Mesothelioma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡